Drugs / Tetanus peptide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02126579 | May 2014 → Nov 2019 | metastatic melanoma, mucosal melanoma | Craig L Slingluff, Jr | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tetanus peptide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02126579 ↗ |
| Known as | Tet | “Participants with resected stage IIB-IV melanoma were vaccinated with seven long melanoma peptides (LPV7) from tyrosinase, gp100, MAGE-A1, MAGE-A10, and NY-ESO-1, each...” PMID 34413169 ↗ Aug 2021 |
| Modality | Peptide | “plus a tetanus helper peptide (Tet) restricted by Class II MHC.” PMID 34413169 ↗ Aug 2021 |
| Route | Subcutaneous | “1.5 mL administered half intradermally and half subcutaneously.” NCT02126579 ↗ |